Diagnostic Tools for Monitoring Kidney Transplant Recipients

Seminars in Nephrology

Volumn 27, Issue 4, 2007, Pages 462-478

  Girlanda, Raffaele ^a   Mannon, Roslyn B ^a   Kirk, Allan D ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

allograft rejection; immunosuppression; Kidney transplantation; monitoring; protocol biopsy

Indexed keywords

ALLOANTIBODY; CYCLOSPORIN; TACROLIMUS;

ARTICLE; BIOPSY; BLOOD; CORRELATION ANALYSIS; CYTOLOGY; DIAGNOSTIC PROCEDURE; DNA POLYMORPHISM; DRUG MONITORING; ENZYME LINKED IMMUNOSPOT ASSAY; FUNCTIONAL ASSESSMENT; GENETIC TRANSCRIPTION; GRAFT DYSFUNCTION; GRAFT FAILURE; GRAFT RECIPIENT; HISTOLOGY; HUMAN; IMAGING; IMMUNOBIOLOGY; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY PARENCHYMA; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MEASUREMENT; MICROARRAY ANALYSIS; PATHOLOGY; PATIENT MONITORING; PHARMACOGENOMICS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEOMICS; RNA ANALYSIS; VIRUS REPLICATION;

DIAGNOSTIC TECHNIQUES AND PROCEDURES; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; MONITORING, PHYSIOLOGIC; POSTOPERATIVE PERIOD;

EID: 34347363121     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2007.03.007     Document Type: Article

References (180)

1. Kasiske B.L., Vasquez M.A., Harmon W.E., et al. Recommendations for the outpatient surveillance of renal transplant recipients. J Am Soc Nephrol 11 (2000) S1-S86
2. Hariharan S., Mcbride M.A., Cherikh W.S., et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 62 (2002) 311-318
3. Kasiske B.L., Andany M., and Danielson B. A thirty percent chronic decline in inverse serum creatinine is an excellent predictor of late renal allograft failure. Am J Kidney Dis 39 (2002) 762-768
4. Govani M.V., Kwon O., Batiuk T.D., et al. Creatinine reduction ratio and 24-hour creatinine excretion on post-transplant day two: simple and objective tools to define graft function. J Am Soc Nephrol 13 (2002) 1645-1649
5. Rodrigo E., Ruiz J.C., Pinera C., et al. Creatinine reduction ratio on post-transplant day two as criterion in defining delayed graft function. Am J Transplant 4 (2004) 1163-1169
6. Kaplan B., Schold J., and Meier-Kriesche H.U. Poor predictive value of serum creatinine for renal allograft loss. Am J Transplant 3 (2003) 1560-1565
7. Nankivell B.J. Predicting glomerular filtration rate after kidney transplantation. Transplantation 59 (1995) 1683-1689
8. Raju D.L., Grover V.K., and Shoker A. Limitations of glomerular filtration rate equations in the renal transplant patient. Clin Transpl 19 (2005) 259-268
9. Gaspari F., Ferrari S., Stucchi N., et al. Performance of different prediction equations for estimating renal function in kidney transplantation. Am J Transplant 4 (2004) 1826-1835
10. Poge U., Gerhardt T., Palmedo H., et al. MDRD equations for estimation of GFR in renal transplant recipients. Am J Transplant 5 (2005) 1306-1311
11. Erlandsen E.J. Reference intervals for serum cystatin C and serum creatinine in adults. Clin Chem Lab Med 36 (1998) 393-397
12. Randers E., Kristensen J.H., Erlandsen E.J., et al. Serum cystatin C as a marker of renal function. Scand J Clin Lab Invest 58 (1998) 585-592
13. Ognibene A., Mannucci E., Caldini A., et al. Cystatin C reference values and aging. Clin Biochem 39 (2006) 658-661
14. Risch L., and Huber A.R. Assessing glomerular filtration rate in renal transplant recipients by estimates derived from serum measurements of creatinine and cystatin C. Clin Chim Acta 356 (2005) 204-211
15. White C., Akbari A., Hussain N., et al. Estimating glomerular filtration rate in kidney transplantation: a comparison between serum creatinine and cystatin C-based methods. J Am Soc Nephrol 16 (2005) 3763-3770
16. Christensson A., Ekberg J., Grubb A., et al. Serum cystatin C is a more sensitive and more accurate marker of glomerular filtration rate than enzymatic measurements of creatinine in renal transplantation. Nephron Physiol 94 (2003) 19-27
17. Poge U., Gerhardt T., Stoffel-Wagner B., et al. Cystatin C-based calculation of glomerular filtration rate in kidney transplant recipients. Kidney Int 70 (2006) 204-210
18. Cimerman N., Brguljan P.M., Krasovec M., et al. Serum cystatin C, a potent inhibitor of cysteine proteinases, is elevated in asthmatic patients. Clin Chim Acta 300 (2000) 83-95
19. Mendiluce A., Bustamante J., Martin D., et al. Cystatin C as a marker of renal function in kidney transplant patients. Transplant Proc 37 (2005) 3844-3847
20. Hartmann A., Eide T., Fauchald P., et al. Serum amyloid A protein is a clinically useful indicator of acute renal allograft rejection. Nephrol Dial Transplant 12 (1997) 161-166
21. Koçak H., Öner-İyidoǧan Y., Gürdöl F., et al. Cystatin-C and creatinine as indices of glomerular filtration rate in the immediate follow-up of renal transplant patients. Clin Exp Med 5 (2005) 14-19
22. Keil M., Pec M.K., Schenn G., et al. Value of serum soluble tumour necrosis factor concentrations in the diagnosis and prognosis of renal graft function. Nephrol Dial Transplant 9 (1994) 815-819
23. Kutukculer N., Clark K., Rigg K.M., et al. The value of post-transplant monitoring of interleukin (IL)-2, IL-3, IL-4, IL-6, IL-8, and soluble CD23 in the plasma of renal allograft recipients. Transplantation 59 (1995) 333-340
24. Waiser J., Budde K., Katalinic A., et al. Interleukin-6 expression after renal transplantation. Nephrol Dial Transplant 12 (1997) 753-759
25. Budde K., Waiser J., Ceska M., et al. Interleukin-8 expression in patients after renal transplantation. Am J Kidney Dis 29 (1997) 871-880
26. Teppo A.M., Tornroth T., Honkanen E., et al. Urinary amino-terminal propeptide of type III procollagen (PIIINP) as a marker of interstitial fibrosis in renal transplant recipients. Transplantation 75 (2003) 2113-2119
27. Sasaki T.M. Increased beta 2-microglobulin (B2M) is useful in the detection of post-transplant lymphoproliferative disease (PTLD). Clin Transpl 11 (1997) 29-33
28. Woo K.T. Beta-2-microglobulin in the assessment of renal function of the transplanted kidney. Nephron 39 (1985) 223-227
29. Schaub S., Wilkins J.A., Antonovici M., et al. Proteomic-based identification of cleaved urinary beta2-microglobulin as a potential marker for acute tubular injury in renal allografts. Am J Transplant 5 (2005) 729-738
30. Backman L., Ringden O., Bjorkhem I., et al. Increased serum beta 2 microglobulin during rejection, cyclosporine-induced nephrotoxicity, and cytomegalovirus infection in renal transplant recipients. Transplantation 42 (1986) 368-371
31. Prischl F., Gremmel F., Schwabe M., et al. Beta-2-microglobulin for differentiation between cyclosporine A nephrotoxicity and graft rejection in renal transplant recipients. Nephron 51 (1989) 330-337
32. Schaub S., Rush D., Wilkins J., et al. Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J Am Soc Nephrol 15 (2004) 219-227
33. Puppo F., Brenci S., Contini P., et al. Increased beta2-microglobulin-free HLA class I heavy chain serum levels in the course of immune responses to viral antigens and to mismatched HLA antigens. Tissue Antigens 55 (2000) 333-341
34. Smith C.A., Gruss H.J., Davis T., et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 73 (1993) 1349-1360
35. Schwab U., Stein H., Gerdes J., et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 299 (1982) 65-67
36. Alzona M., Jack H.M., Fisher R.I., et al. CD30 defines a subset of activated human T cells that produce IFN-gamma and IL-5 and exhibit enhanced B cell helper activity. J Immunol 153 (1994) 2861-2867
37. Susal C., Pelzl S., Dohler B., et al. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 13 (2002) 1650-1656
38. Pelzl S., Opelz G., Wiesel M., et al. Soluble CD30 as a predictor of kidney graft outcome. Transplantation 73 (2002) 3-6
39. Vaidya S., Partlow D., Barnes T., et al. Soluble CD30 concentrations in ESRD patients with and without panel reactive HLA antibodies. Clin Transpl 20 (2006) 461-464
40. Matinlauri I.H., Kyllonen L.E.J., Salmela K.T., et al. Serum sCD30 in monitoring of alloresponse in well HLA-matched cadaveric kidney transplantations. Transplantation 80 (2005) 1809-1812
41. Dong W., Shunliang Y., Weizhen W., et al. Prediction of acute renal allograft rejection in early post-transplantation period by soluble CD30. Transpl Immunol 16 (2006) 41-45
42. Weimer R., Susal C., Yildiz S., et al. Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens. Am J Transplant 6 (2006) 1865-1874
43. Dugre F.J., Gaudreau S., Belles-Isles M., et al. Cytokine and cytotoxic molecule gene expression determined in peripheral blood mononuclear cells in the diagnosis of acute renal rejection. Transplantation 70 (2000) 1074-1080
44. Huber C., Batchelor J.R., Fuchs D., et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 160 (1984) 310-316
45. Sadeghi M., Daniel V., Weimer R., et al. Differential early posttransplant cytokine responses in living and cadaver donor renal allografts. Transplantation 75 (2003) 1351-1355
46. Kusaka M., Pratschke J., Wilhelm M.J., et al. Activation of inflammatory mediators in rat renal isografts by donor brain death. Transplantation 69 (2000) 405-410
47. Sadeghi M., Daniel V., Naujokat C., et al. Association of high pretransplant sIL-6R plasma levels with acute tubular necrosis in kidney graft recipients. Transplantation 81 (2006) 1716-1724
48. Simmons E.M., Langone A., Sezer M.T., et al. Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients. Transplantation 79 (2005) 914-919
49. Gibbs P.J., Tan L.C., Sadek S.A., et al. Quantitative detection of changes in cytokine gene expression in peripheral blood mononuclear cells correlates with and precedes acute rejection in renal transplant recipients. Transpl Immunol 14 (2005) 99-108
50. Simon T., Opelz G., Wiesel M., et al. Serial peripheral blood interleukin-18 and perforin gene expression measurements for prediction of acute kidney graft rejection. Transplantation 77 (2004) 1589-1595
51. Sabek O., Dorak M.T., Kotb M., et al. Quantitative detection of T-cell activation markers by real-time PCR in renal transplant rejection and correlation with histopathologic evaluation. Transplantation 74 (2002) 701-707
52. Tan L., Martin Howell W., Smith J.L., et al. Sequential monitoring of peripheral T-lymphocyte cytokine gene expression in the early post renal allograft period. Transplantation 71 (2001) 751-759
53. Shoker A., George D., Yang H., et al. Heightened CD40 ligand gene expression in peripheral CD4+ T cells from patients with kidney allograft rejection. Transplantation 70 (2000) 497-505
54. Dudding L., Haskill S., Clark B.D., et al. Cytomegalovirus infection stimulates expression of monocyte-associated mediator genes. J Immunol 143 (1989) 3343-3352
55. Mihm S. High inflammatory activity is associated with an increased amount of IFN-gamma transcripts in peripheral blood cells of patients with chronic hepatitis C virus infection. Med Microb Immunol 185 (1996) 95-102
56. Hoffmann S., Park J., Jacobson L.M., et al. Donor genomics influence graft events: the effect of donor polymorphisms on acute rejection and chronic allograft nephropathy. Kidney Int 66 (2004) 1686-1693
57. Sankaran D., Asderakis A., Ashraf S., et al. Cytokine gene polymorphisms predict acute graft rejection following renal transplantation. Kidney Int 56 (1999) 281-288
58. Asderakis A., Sankaran D., Dyer P., et al. Association of polymorphisms in the human interferon gamma and interleukin-10 gene with acute and chronic kidney transplant outcome: the cytokine effect on transplantation. Transplantation 71 (2001) 674-678
59. Mestre M. Longitudinal study of the frequency of cytotoxic T cell precursors in kidney allograft recipients. Clin Exp Immunol 104 (1996) 108-114
60. Zanker B. Evidence that functional deletion of donor-reactive T lymphocytes in kidney allograft recipients can occur at the level of cytotoxic T cells, IL-2-producing T cells, or both. A limiting dilution study. Transplantation 56 (1993) 628-632
61. Heeger P.S., Greenspan N.S., Kuhlenschmidt S., et al. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol 163 (1999) 2267-2275
62. Hirschhorn K., Bach F., Kolodny R.L., et al. Immune response and mitosis of human peripheral blood lymphocytes in vitro. Science 142 (1963) 1185-1187
63. Sharrock C.E.M., Kaminski E., and Man S. Limiting dilution analysis of human T cells: a useful clinical tool. Immunol Today 11 (1990) 281-286
64. Petersen S.L., Sidorov I.A., Russell C.A., et al. Limiting dilution analysis of interleukin-2 producing helper T-cell frequencies as a tool in allogeneic hematopoietic cell transplantation. Transplantation 80 (2005) 573-581
65. Altman J.D., Moss P.A.H., Goulder P.J.R., et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274 (1996) 94-96
66. Scriba T.J., Purbhoo M., Day C.L., et al. Ultrasensitive detection and phenotyping of CD4+ T cells with optimized HLA class II tetramer staining. J Immunol 175 (2005) 6334-6343
67. Tary-Lehmann M., Hricik D.E., Justice A.C., et al. Enzyme-linked immunosorbent assay spot detection of interferon-gamma and interleukin 5-producing cells as predictive marker for renal allograft failure. Transplantation 66 (1998) 219-224
68. Gebauer B.S., Hricik D.E., Atallah A., et al. Evolution of the enzyme-linked immunosorbent spot assay for post-transplant alloreactivity as a potentially useful immune monitoring tool. Am J Transplant 2 (2002) 857-866
69. Hernandez-Fuentes M.P., Warrens A.N., and Lechler R.I. Immunologic monitoring. Immunol Rev 196 (2003) 247-264
70. Hricik D.E., Rodriguez V., Riley J., et al. Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients. Am J Transplant 3 (2003) 878-884
71. Najafian N., Salama A.D., Fedoseyeva E.V., et al. Enzyme-linked immunosorbent spot assay analysis of peripheral blood lymphocyte reactivity to donor HLA-DR peptides: potential novel assay for prediction of outcomes for renal transplant recipients. J Am Soc Nephrol 13 (2002) 252-259
72. Kowalski R., Post D., Schneider M.C., et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transpl 17 (2003) 77-88
73. Kowalski R.J., Post D.R., Mannon R.B., et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 82 (2006) 663-668
74. Kissmeyer-Nielsen F., Olsen S., Petersen V.P., et al. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 7465 (1966) 662-665
75. Patel R., and Terasaki P.I. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 280 (1969) 735-739
76. Crespo M., Pascual M., Tolkoff-Rubin N., et al. Acute humoral rejection in renal allograft recipients: incidence, serology and clinical characteristics. Transplantation 71 (2001) 652-658
77. Terasaki P.I. Humoral theory of transplantation. Am J Transplant 3 (2003) 665-673
78. Terasaki P.I., and Ozawa M. Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial. Transplantation 80 (2005) 1194-1197
79. Colvin R.B., and Smith R.N. Antibody-mediated organ-allograft rejection. Nat Rev Immunol 5 (2005) 807-817
80. Lee P.C., Terasaki P.I., Takemoto S.K., et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 74 (2002) 1192-1194
81. Racusen L.C., Colvin R.B., Solez K., et al. Antibody-mediated rejection criteria-an addition to the Banff '97 classification of renal allograft rejection. Am J Transplant 3 (2003) 708-714
82. Zwirner N.W., Fernandez-Vina M.A., and Stastny P. MICA, a new polymorphic HLA-related antigen, is expressed mainly by keratinocytes, endothelial cells, and monocytes. Immunogenetics 47 (1997) 139-148
83. Mizutani K., Terasaki P.I., Shih R.N., et al. Frequency of MIC antibody in rejected renal transplant patients without HLA antibody. Hum Immunol 67 (2006) 223-229
84. Zwirner N.W., Marcos C.Y., Mirbaha F., et al. Identification of MICA as a new polymorphic alloantigen recognized by antibodies in sera of organ transplant recipients. Hum Immunol 61 (2000) 917-924
85. Zou Y., Heinemann F.M., Grosse-Wilde H., et al. Detection of anti-MICA antibodies in patients awaiting kidney transplantation, during the post-transplant course, and in eluates from rejected kidney allografts by luminex flow cytometry. Hum Immunol 67 (2006) 230-237
86. Sumitran-Holgersson S., Wilczek H.E., Holgersson J., et al. Identification of the nonclassical HLA molecules, mica, as targets for humoral immunity associated with irreversible rejection of kidney allografts. Transplantation 74 (2002) 268-277
87. Gibney E.M., Cagle L.R., Freed B., et al. Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification. Nephrol Dial Transplant 21 (2006) 2625-2629
88. Kuypers D.R.J., Vanrenterghem Y., Squifflet J.P., et al. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit 25 (2003) 609-622
89. Trepanier D.J., Gallant H., Legatt D.F., et al. Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update. Clin Biochem 31 (1998) 345-351
90. Thervet E., Legendre C., Beaune P., et al. Cytochrome P450 3A polymorphisms and immunosuppressive drugs. Pharmacogenomics 6 (2005) 37-47
91. Fredericks S., Holt D.W., and MacPhee I.A. The pharmacogenetics of immunosuppression for organ transplantation: a route to individualization of drug administration. Am J Pharmacogenomics 3 (2003) 291-301
92. Kronbach T. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 43 (1988) 630-635
93. Venkataramanan R. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 29 (1995) 404-430
94. Tsuchiya N., Satoh S., Tada H., et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 78 (2004) 1182-1187
95. Mourad M., Mourad G., Wallemacq P., et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation 80 (2005) 977-984
96. Haehner B.D., Gorski J.C., Vandenbranden M., et al. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol 50 (1996) 52-59
97. Zhang Y., and Benet L.Z. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 40 (2001) 159-168
98. MacPhee I.A.M., Fredericks S., Tai T., et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 4 (2004) 914-919
99. Thiebaut F., Tsuruo T., Hamada H., et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84 (1987) 7735-7738
100. Haufroid V., Mourad M., Van Kerckhove V., et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14 (2004) 147-154
101. Kirk A.D., Ford E., Fischer S., et al. Epstein Barr virus (EBV) as a biological indicator of immunosuppression in human renal transplantation (2006) Paper presented at: World Transplant Congress; Jul 22-27; Boston, MA.
102. Racusen L.C., Solez K., Colvin R.B., et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 55 (1999) 713-723
103. Shapiro R., Randhawa P., Jordan M.L., et al. An analysis of early renal transplant protocol biopsies-the high incidence of subclinical tubulitis. Am J Transplant 1 (2001) 47-50
104. Mengel M., Mueller I., Behrend M., et al. Prognostic value of cytotoxic T-lymphocytes and CD40 in biopsies with early renal allograft rejection. Transpl Int 17 (2004) 293-300
105. Collins A.B., Schneeberger E.E., Pascual M.A., et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 10 (1999) 2208-2214
106. Bohmig G.A., Exner M., Habicht A., et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 13 (2002) 1091-1099
107. Rush D.N. Histological findings in early routine biopsies of stable renal allograft recipients. Transplantation 57 (1994) 208-211
108. Rush D.N., Nickerson P., Jeffery J.R., et al. Protocol biopsies in renal transplantation: research tool or clinically useful?. Curr Opin Nephrol Hypertens 7 (1998) 691-694
109. Nickerson P., Jefferey J., Gough J., et al. Effect of increasing baseline immunosuppression on the prevalence of clinical and subclinical rejection: a pilot study. J Am Soc Nephrol 10 (1999) 1801-1805
110. Cosio F.G., Grande J.P., Wadei H., et al. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 5 (2005) 2464-2472
111. Dallman M.J., Roake J., Hughes D., et al. Sequential analysis of IL-2 gene transcription in renal transplants. Transplantation 53 (1992) 683-685
112. Kirk A.D., Bollinger R.R., and Finn O.J. Rapid, comprehensive analysis of human cytokine mRNA and its application to the study of acute renal allograft rejection. Hum Immunol 43 (1995) 113-128
113. McLean A.G., Hughes D., Welsh K.I., et al. Patterns of graft infiltration and cytokine gene expression during the first 10 days of kidney transplantation. Transplantation 63 (1997) 374-380
114. Strehlau J., Pavlakis M., Lipman M., et al. Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. PNAS 94 (1997) 695-700
115. Lipman M.L., Stevens A.C., and Strom T.B. Heightened intragraft CTL gene expression in acutely rejecting renal allografts. J Immunol 152 (1994) 5120-5127
116. Sharma V.K., Bologa R.M., Li B., et al. Molecular executors of cell death-differential intrarenal expression of fas ligand, fas, granzyme b, and perforin during acute and/or chronic rejection of human renal allografts. Transplantation 62 (1996) 1860-1866
117. Segerer S. Expression of chemokines and chemokine receptors during human renal transplant rejection. Am J Kidney Dis 37 (2001) 518-531
118. Faull R.J. Tubular expression of intercellular adhesion molecule-1 during renal allograft rejection. Transplantation 48 (1989) 226-230
119. Park S.Y., Kim H.W., Moon K.C., et al. mRNA expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in acute renal allograft rejection. Transplantation 69 (2000) 2554-2560
120. Sharma V.K., Bologa R.M., Xu G.P., et al. Intragraft TGF-beta 1 mRNA: a correlate of interstitial fibrosis and chronic allograft nephropathy. Kidney Int 49 (1996) 1297-1303
121. Jain S., Furness P.N., Nicholson M.L., et al. The role of transforming growth factor beta in chronic renal allograft nephropathy. Transplantation 69 (2000) 1759-1766
122. Baboolal K. Molecular and structural consequences of early renal allograft injury. Kidney Int 61 (2002) 686-696
123. Vasconcellos L.M., Asher F., Schachter D., et al. Cytotoxic lymphocyte gene expression in peripheral blood leukocytes correlates with rejecting renal allografts. Transplantation 66 (1998) 562-566
124. Hoffmann S.C., Kampen R.L., Amur S., et al. Molecular and immunohistochemical characterization of the onset and resolution of human renal allograft ischemia-reperfusion injury. Transplantation 74 (2002) 916-923
125. Avihingsanon Y., Ma N., Pavlakis M., et al. On the intraoperative molecular status of renal allografts after vascular reperfusion and clinical outcomes. J Am Soc Nephrol 16 (2005) 1542-1548
126. Cheng O.H., Kampen R.L., Hoffmann S.C., et al. Look into the crystal ball: using gene expression arrays to predict chronic allograft nephropathy (CAN) (2006) Presented at: World Transplant Congress; July 22-27; Boston, MA
127. Hoffmann S.C., Pearl J.P., Blair P.J., et al. Immune profiling: molecular monitoring in renal transplantation. Front Biosci 8 (2003) 444-462
128. Hoffmann S.C., Hale D.A., Kleiner D.E., et al. Functionally significant renal allograft rejection is defined by transcriptional criteria. Am J Transplant 5 (2005) 573-581
129. Mannon R.B., Hoffmann S.C., Kampen R.L., et al. Molecular evaluation of BK polyomavirus nephropathy. Am J Transplant 5 (2005) 2883-2893
130. Lockhart D.J., and Winzeler E.A. Genomics, gene expression and DNA arrays. Nature 405 (2000) 827-836
131. Mansfield E.S., and Sarwal M.M. Arraying the orchestration of allograft pathology. Am J Transplant 4 (2004) 853-862
132. Hyatt G., Melamed R., Park R., et al. Gene expression microarrays: glimpses of the immunological genome. Nat Immunol 7 (2006) 686-691
133. Sarwal M.M. Chipping into the human genome: novel insights for transplantation. Immunol Rev 210 (2006) 138-155
134. Akalin E., Hendrix R.C., Giri Polavarapu R., et al. Gene expression analysis in human renal allograft biopsy samples using high-density oligoarray technology. Transplantation 72 (2001) 948-953
135. Sarwal M., Chua M.S., Kambham N., et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 349 (2003) 125-138
136. Hippen B.E., DeMattos A., Cook W.J., et al. Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts. Am J Transplant 5 (2005) 2248-2252
137. Scherer A., Krause A., Walker J.R., et al. Early prognosis of the development of renal chronic allograft rejection by gene expression profiling of human protocol biopsies. Transplantation 75 (2003) 1323-1330
138. Donauer J., Rumberger B., Klein M., et al. Expression profiling on chronically rejected transplant kidneys. Transplantation 76 (2003) 539-547
139. Hotchkiss H., Chu T.T., Hancock W.W., et al. Differential expression of profibrotic and growth factors in chronic allograft nephropathy. Transplantation 81 (2006) 342-349
140. Flechner S.M., Kurian S.M., Head S.R., et al. Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes. Am J Transplant 4 (2004) 1475-1489
141. Radermacher J., Mengel M., Ellis S., et al. The renal arterial resistance index and renal allograft survival. N Engl J Med 349 (2003) 115-124
142. Elster E.A., Hale D.A., Mannon R.B., et al. Surgical transplant physical examination: correlation of renal resistance index and biopsy-proven chronic allograft nephropathy. J Am Coll Surg 200 (2005) 552-556
143. Gorbach A., Simonton D., Hale D.A., et al. Objective, real-time, intraoperative assessment of renal perfusion using infrared imaging. Am J Transplant 3 (2003) 988-993
144. Szabo Z., Xia J., Mathews W.B., et al. Future direction of renal positron emission tomography. Semin Nucl Med 36 (2006) 36-50
145. Grenier N., Hauger O., Cimpean A., et al. Update of renal imaging. Semin Nucl Med 36 (2006) 3-15
146. Thompson R.E., Hewitt C.R., Piper D.J., et al. Competitive idiotype-anti-idiotype immunoassay for adenosine deaminase binding protein in urine. Clin Chem 31 (1985) 1833-1837
147. Tolkoff-Rubin N.E. Diagnosis of tubular injury in renal transplant patients by a urinary assay for a proximal tubular antigen, the adenosine-deaminase-binding protein. Transplantation 41 (1986) 593-597
148. Fernandez-Fresnedo G., Plaza J.J., Sanchez-Plumed J., et al. Proteinuria: a new marker of long-term graft and patient survival in kidney transplantation. Nephrol Dial Transplant 19 (2004) iii47-iii51
149. Keane W.F. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 33 (1999) 1004-1010
150. Gill J., Zalunardo N., Nussbaumer G., et al. Peri-transplant change in proteinuria among pre-emptive kidney transplant recipients. [abstract]. Transplantation 82 Suppl 2 (2006) 822-823
151. Rosenkranz A.R., and Mayer G. Proteinuria in the transplanted patient. Nephrol Dial Transplant 5 (2000) 1290-1292
152. Williams M., Polly S., Swanson S.J., et al. Alloantibody-mediated acute rejection with features similar to focal segmental glomerulosclerosis (FSGS) successfully treated with intravenous immunoglobulin (IVIg). [abstract]. J Am Soc Nephrol 12 (2001) 952A
153. Roberti I., Reisman L., Burrows L., et al. Urine cytology and urine flow cytometry in renal transplantation-a prospective double blind study. Transplantation 59 (1995) 495-500
154. Roberti I., Panico M., and Reisman L. Urine flow cytometry as a tool to differentiate acute allograft rejection from other causes of acute renal graft dysfunction. Transplantation 64 (1997) 731-734
155. Roberti I., Panico M., and Reisman L. Urine flow cytometry as a predictor of renal allograft function. Transplantation 63 (1997) 781-782
156. Roberti I., and Reisman L. Serial evaluation of cell surface markers for immune activation after acute renal allograft rejection by urine flow cytometry: correlation with clinical outcome. Transplantation 71 (2001) 1317-1320
157. Randhawa P., and Brennan D.C. BK virus infection in transplant recipients: an overview and update. Am J Transplant 6 (2006) 2000-2005
158. Kwon O., Molitoris B.A., Pescovitz M., et al. Urinary actin, interleukin-6, and interleukin-8 may predict sustained ARF after ischemic injury in renal allografts. Am J Kidney Dis 41 (2003) 1074-1087
159. Tatapudi R.R., Muthukumar T., Dadhania D., et al. Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney Int 65 (2004) 2390-2397
160. Akalin E., Dikman S., Murphy B., et al. Glomerular infiltration by CXCR3+ ICOS+ activated T cells in chronic allograft nephropathy with transplant glomerulopathy. Am J Transplant 3 (2003) 1116-1120
161. Hu H., Aizenstein B.D., Puchalski A., et al. Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction. Am J Transplant 4 (2004) 432-437
162. Grandaliano G., Gesualdo L., Ranieri E., et al. Monocyte chemotactic peptide-1 expression and monocyte infiltration in acute renal transplant rejection. Transplantation 63 (1997) 414-420
163. Brown F.G., Nikolic-Paterson D.J., Chadban S.J., et al. Urine macrophage migration inhibitory factor concentrations as a diagnostic tool in human renal allograft rejection. Transplantation 71 (2001) 1777-1783
164. Parikh C.R., Jani A., Mishra J., et al. Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am J Transplant 6 (2006) 1639-1645
165. Li B., Hartono C., Ding R., et al. Noninvasive diagnosis of renal allograft rejection by measurement of messenger RNA for Perforin and Granzyme B in urine. N Engl J Med 344 (2001) 947-954
166. Kotsch K., Mashreghi M.F., Bold G., et al. Enhanced granulysin mRNA expression in urinary sediment in early and delayed acute renal allograft rejection. Transplantation 77 (2004) 1866-1875
167. Teppo A.M., von Willebrand E., Honkanen E., et al. Soluble intercellular adhesion molecule-1 (Sicam-1) after kidney transplantation: the origin and role of urinary sicam-1?. Transplantation 71 (2001) 1113-1119
168. Matz M., Beyer J., Wunsch D., et al. Early post-transplant urinary IP-10 expression after kidney transplantation is predictive of short- and long-term graft function. Kidney Int 69 (2006) 1683-1690
169. Muthukumar T., Dadhania D., Ding R., et al. Messenger RNA for FOXP3 in the urine of renal allograft recipients. N Engl J Med 353 (2005) 2342-2351
170. Lederer S.R., Friedrich N., Regenbogen C., et al. Non-invasive monitoring of renal transplant recipients: urinary excretion of soluble adhesion molecules and of the complement-split product C4d. Nephron Clin Pract 94 (2003) c19-c26
171. Bechtel U. Assessment of soluble adhesion molecules (sICAM-1, sVCAM-1, sELAM-1) and complement cleavage products (sC4d, sC5b-9) in urine. Clinical monitoring of renal allograft recipients. Transplantation 58 (1994) 905-911
172. Hosaka B., Park S.I., Felipe C.R., et al. Predictive value of urinary retinol binding protein for graft dysfunction after kidney transplantation. Transplant Proc 35 (2003) 1341-1343
173. Camara N.O., Silva M.S., Nishida S., et al. Proximal tubular dysfunction is associated with chronic allograft nephropathy and decreased long-term renal-graft survival. Transplantation 78 (2004) 269-275
174. Teppo A.M., Honkanen E., Finne P., et al. Increased urinary excretion of alpha1-microglobulin at 6 months after transplantation is associated with urinary excretion of transforming growth factor-beta1 and indicates poor long-term renal outcome. Transplantation 78 (2004) 719-724
175. O'Riordan E., Gross S.S., and Goligorsky M.S. Technology insight: renal
176. Kaiser T., Kamal H., Rank A., et al. Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. Blood 104 (2004) 340-349
177. Clarke W., Silverman B.C., Zhang Z., et al. Characterization of renal allograft rejection by urinary proteomic analysis. Ann Surg 237 (2003) 660-665
178. O'Riordan E., Orlova T.N., Mei J., et al. Bioinformatic analysis of the urine proteome of acute allograft rejection. J Am Soc Nephrol 15 (2004) 3240-3248
179. El Essawy B., Otu H.H., Choy B., et al. Proteomic analysis of the allograft response. Transplantation 82 (2006) 267-274
180. Germain R.N., Miller M.J., Dustin M.L., et al. Dynamic imaging of the immune system: progress, pitfalls and promise. Nat Rev Immunol 6 (2006) 497-507